COX-2 is not involved in thromboxane biosynthesis by activated human platelets

Journal of Physiology and Pharmacology

Volumn 50, Issue 4, 1999, Pages 661-667

  Patrignani, Paola ^a   Sciulli, M G ^a   Manarini, S ^b   Santini, G ^a   Cerletti, C ^b   Evangelista, V ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Aspirin; COX 1; COX 2; Platelets; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; LIPOPOLYSACCHARIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN H; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE;

CONFERENCE PAPER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MONOCYTE; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; VASCULAR DISEASE;

ADULT; ASPIRIN; BLOOD PLATELETS; BLOTTING, WESTERN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ISOENZYMES; LIPOPOLYSACCHARIDES; MALE; MEMBRANE PROTEINS; MONOCYTES; NITROBENZENES; PLATELET ACTIVATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PROTEIN ISOFORMS; SULFONAMIDES; THROMBOXANES;

EID: 0033377768     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Helgason CM, Tortorice KL, Winkler SR, Penney DW, Shuler JJ, McClelland TJ, Brace LD. Aspirin response and failure in cerebral infarction. Stroke 1993; 24: 345-350.
2. Helgason CM, Bolin JA, Hoff SR, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-2336.
3. Vejar M, Fragasso G, Hackett D, Lipkin DP, Maseri A, Born GVR, Ciabattoni G, Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemostas 1990; 63: 163-168.
4. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294.
5. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets: acetylation of a particulate protein fraction. J Clin Invest 1975; 56: 624-632.
6. 2 synthase. Nature Structural Biol 1995; 2: 637-643.
7. Smith WL, Garavito RM, DeWitt, DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271: 33157-33160.
8. Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997; 96: 1109-1116.
9. Takahashi Y, Ueda N, Yoshimoto T, Yokoyama C, Miyata A, Tanabe T, Fuse I, Hattori A, Shibata A. Immunoaffinity purification and cDNA cloning of human platelet prostaglandin endoperoxide synthase (cyclooxygenase). Biochem Biophys Res Commun 1992; 182: 433-438.
10. Weber A-A, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353: 900.
11. Panara MR, Greco A, Santini G, Sciulli MG, Rotondo MT, Padovano R, Di Giamberardino M, Cipollone F, Cuccurullo F, Patrono C, Patrignani P. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio-phenyl)-1-indanone (L-745, 337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Br J Pharmacol 1995; 116: 2429-2434.
12. Piccardoni P, Evangelista V, Piccoli A, de Gaetano G, Walz A, Cerletti C. Thrombin-activated platelets release two NAP-2 variants that stimulate polymorphonuclear leukocytes. Thromb Haemost 1996; 76: 780-785.
13. 2α in human urine. J Endocrinol Invest 1979; 2: 173-182.
14. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-1372.
15. De Lean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 1978; 235: E97-E102.
16. Patrono C, Coller B, Dalen JE, Fuster V, Gent M, Harher LA, Hirsh J, Roth G. Platelet-active drugs. The relationships among dose, effectiveness, and side effects. Chest 1998; 114: 470S-488S.
17. Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, Simard D, Silver FL, Hachinski V, Clagett GP, Barnes R, Spence JD. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial. Lancet 1999; 353: 2179-2184.
18. Maseri A, Biasucci LM, Liuzzo G. Inflammation in ischemic heart disease. C reactive protein concentrations may provide useful information on risk. BMJ 1996; 321: 1049-1050.